Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose co-administration of NNC0480-0389 and semaglutide in healthy Japanese men
jRCT2071210021Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0480-0389 and semaglutide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Treatment-emergent adverse events. Started May 2021; status: completed.
02
Drugs
NNC0480-0389semaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2071210021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210021.